COUGAR BIOTECHNOLOGY BEGINS TRIAL OF PROSTATE CANCER DRUG

A A

Cougar Biotechnology announced that the first patient has been enrolled in a Phase I trial of the company's drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer.

The Phase I trial of CB7630 will be conducted at the University of California San Francisco Comprehensive Cancer Center. The trial is an open-label, dose-escalating study to evaluate the safety and efficacy of CB7630 administered daily to patients with chemotherapy-naive hormone refractory prostate cancer with a rising prostate-specific antigen despite hormonal therapy.